RT Journal Article
T1 Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: A systematic review
A1 Ruiz-Sastre, Paloma
A1 Gómez-Sánchez-Lafuente, Carlos
A1 Martín-Martín, Jaime
A1 Herrera-Imbroda, Jesús
A1 Mayoral Cleries, Fermín
A1 Santos-Amaya, Ignacio Miguel
A1 Rodriguez-de-Fonseca, Fernando
A1 Guzmán-Parra, José
A1 Rivera-González, Patricia
A1 Suárez-Pérez, Juan
K1 Farmacología - Uso terapéutico
K1 Psicosis maniacodepresiva - Efectos de los medicamentos
AB Background: The various pharmacological interventions, ranging from mood stabilizers and antipsychotics to antidepressants, reflect the diff/iculty of treating depressive/manic symptomatology of bipolar disorder (BD). Among a broad range of mechanisms implicated, immune dysregulation may contribute to the increased inflammation that influences the course of BD. Inflammatory, neurotrophic and oxidative stress factors may be identified as promising peripheral biomarkers in brain functioning, perhaps serving as predictors of an effective response to treatment for BD. The present systematic review aimed to examine the evidence supporting the pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in BD. Methods: PubMed, PsychINFO, Scopus and Web of Science were searched from inception to May 2024 by two independent reviewers. A total of 40 studies with 3371 patients with diagnosis and intervention of BD were selected. Results: Inconsistencies in the effects of pharmacological treatments on the connection between the expected anti- inflammatory response and symptomatologic improvement were identified. Mood stabilizers (lithium), antipsychotics (quetiapine), antidepressants (ketamine) or their combination were described to increase both pro- inflammatory (TNFα, IL-6) and anti-inflammatory (IL-4, IL-8) factors. Other medications, such as memantine and dextromethorphan, autoimmune (infliximab) non-steroidal anti-inflammatory (aspirin, celecoxib) drugs, antidiabetics (pioglitazone), and even dietary supplementation (omega-3), or their combination, clearly decrease inflammatory factors (TNFα, IL-6, IL-1β, C-reactive protein) and/or increase the neurotrophic factor BDNF in BD patients. Conclusion: Inflammation in BD requires further investigation to understand the underlying immunologic mechanism, to identify predictors of treatment response, and to make informed decisions about the use and development of more effective pharmacological interventions for BD.
PB Elsevier
YR 2024
FD 2024-06-13
LK https://hdl.handle.net/10630/31868
UL https://hdl.handle.net/10630/31868
LA eng
NO RICORDS Red de Investigación en Atención Primaria de Adicciones (RIAPAd), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación and European Regional Development Funds-European Union (ERDF-EU), grant number RD21/0009/0003; ISCIII, ERDF-EU, grant number PI22/00427; Ministerio de Sanidad, Delegación de Gobierno para el Plan Nacional sobre Drogas (PND), grant numbers 2019I040, 2020I048 and 2022I020; Proyectos de Excelencia I + D + i (PAIDI 2020), Consejería de Universidad, Investigación e Innovación, Junta de Andalucía, grant number PI21/00291. PR-S (CM21/00097), CG-S-L (CM19/00240) and JH-I (CM21/00255) hold “Rio Hortega” research contracts from the National System of Health, ISCIII, ERDF-EU. Patricia Rivera is supported by the research contract “Miguel Servet” (CP19/00068) of the National System of Health, ERDF-EU-ISCIII, cofunded by European Social Fund, “Investing in your future”, Government of Spain. Funding for open access charge: Universidad de Málaga / CBUA. The funding sources had no further role in study design; in the collection, analysis and interpretation of data; in writing of the report; and in the decision to submit the paper for publication.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026